Listed On
BSE & NSE
Listed On
Issue Price
₹1,083
Issue Price
Listing Price
₹2,112
Listing Price
Listing Gains
+₹1028.80 (+95.00%)
Listing Gains
Bidding Dates
16 Jul - 20 Jul '21
Bidding Dates
Min. Investment
₹13,949
Min. Investment
Lot Size
13.00
Lot Size
Price Range
₹1073 - ₹1083
Price Range
Issue Size
495 Cr
Issue Size
Tatva Chintan manufactures speciality chemicals like structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts, pharmaceutical and agrochemical intermediates.
They serve customers across industries like petroleum, pharmaceutical, agro-chemicals, automotive, paints, coatings and personal care to name a few.
Apart from supplying the domestic market, they also export products to more than 25 countries including the US, UK, China and Japan.
Out of Rs. 500 crore issue size, upto Rs. 225 crore was fresh issue whereas balance upto Rs. 275 crore was offer for sale of equity shares.
The company is planning to utilise the amount raised through IPO for capital expenditure at two of its facilities and the balance to meet general corporate requirements.
Tatva Chintan is a leader amongst SDA and PTC manufacturers. They have a monopoly in manufacturing SDAs for zeolites in India and even globally, they stand second position. They strive to maintain the high-quality of their products. More than 70% of their revenue comes from exports. These factors ensure consistent growth in the industry.
Strengths:
They enjoy a monopoly in India by being the only manufacturer of SDAs for zeolites. Significant revenue comes from exports to countries like the US, UK, China, South Africa and Japan. Their varied product line for industries like automotive, agrochemicals, pharmaceuticals, petroleum, etc., gives them sufficient diversity.
Weaknesses:
Tatva Chintan is dependent on limited raw material suppliers, which also exposes them to cost fluctuations. If timely delivery of required raw materials is not available, it can affect the quality standard of their products.
Opportunities:
They stand in the second position globally in manufacturing SDAs for zeolites. This gives Tatva Chintan a lot of scope to expand in global markets and serve additional industries.
Threats:
Outbreaks of pandemics like COVID 19 and global lockdown or slowdown have a major impact on the company. Change of international economic policies and trade agreements between countries can majorly impact the export revenue.
You can apply for the Tatva Chintan Pharma Chem Ltd. IPO in these ways:
UPI
Link your personal bank A/C to a trusted UPI ID and map it with your TradeSmart account. Now, proceed further to book your IPO. On acceptance of the mandate, the bid amount will get blocked in your bank account Learn more.
Demat Account
1. If you are an Existing TradeSmart demat account holder and wish to apply for an Tatva Chintan Pharma Chem Ltd. click here.
2. If you don't have a TradeSmart Account? Sign up.
What are the important dates related to Tatva Chintan Pharma IPO?
The issue opened on July 16, 2021, and closed on July 20, 2021. The date of allotment was July 26, 2021. And the listing date is July 29, 2021.
Where is the Tatva Chintan IPO getting listed?
The shares of Tatva Chintan will be listed on both NSE and BSE.
Who is the registrar for the Tatva Chintan Pharma Chem IPO?
The registrar of Tatva Chintan Pharma Chem IPO is Link Intime India Pvt. Ltd.
What are the lot size and the minimum order quantity for the Tatva Chintan IPO?
Both the lot size and minimum order quantity of the Tatva Chintan IPO is 13 shares.
Who are the lead managers to the issue?
ICICI Securities and JM Financial are the lead managers for Tatva Chintan IPO.